SequelSEC

ADAPTIN BIO, INC. APTN

Biological Products, (No Diagnostic Substances) · CIK 0001938571 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$5.41M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ADAPTIN BIO, INC. (APTN) reported net income of -$5.17M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from ADAPTIN BIO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

ADAPTIN BIO, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$5.41M-$2.57M-$85.59K
Net income-$5.17M-$3.12M-$85.59K
Research & development$1.77M$1.82MUnavailable
Weighted-average diluted sharesshares 7.81Mshares 3.25Mshares 5.00M
Pretax income-$5.17M-$3.12MUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.66$-0.96$-0.02
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$3.64M$745.29K$85.59K
Selling & marketingUnavailableUnavailableUnavailable

Balance

ADAPTIN BIO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$459.17K$34.08K$380
Total assets$619.16K$239.42K$380
Current assets$619.16K$45.54K$380
Total liabilities$2.11M$4.34M$113.28K
Current liabilities$2.11M$4.34M$113.28K
Total equity incl. NCI-$1.49M-$4.10M-$977.56K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.51M$1.36MUnavailable

Cash flow

ADAPTIN BIO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$4.78M-$649.28K-$81.04K
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$5.20M$678.61K$80.92K
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$496.86KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

ADAPTIN BIO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.29x0.01x0.00x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open APTN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.